The companies signed a letter of intent to use Sanofi’s protein-based antigens and GSK’s adjuvant technology to develop a recombinant DNA-based vaccine. Sanofi already has agreements to develop a recombinant DNA vaccine with U.S. federal authorities and an mRNA vaccine with Translate Bio.